A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Clinical trial NCT07358676 · RECRUITING

Trial details

NCT number: NCT07358676
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer (SCLC)SCLC, Extensive Stage

Start date: 2026-02-01
Primary completion: 2027-01-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.